Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | DRD4 | P21917 | 4/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | LSS | P48449 | 1/20 | 0.51 |
| ▸ | ACHE | P22303 | 1/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.49 |
| ▸ | DRD3 | P35462 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | PRKCI | P41743 | 1/20 | 0.47 |
| ▸ | CHKA | P35790 | 1/20 | 0.47 |
| ▸ | CASP1 | P29466 | 1/20 | 0.47 |
| ▸ | CASP4 | P49662 | 1/20 | 0.47 |
| ▸ | CASP5 | P51878 | 1/20 | 0.47 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8251460 | 0.84 | POLB (0.56) | POLBDRD4KDM4ELSSDRD2 | |
| SCHEMBL9516128 | 0.84 | POLB (0.56) | POLBDRD4KDM4EALDH1A1LSS | |
| SCHEMBL12261943 | 0.83 | DRD4 (0.77) | POLBDRD4DRD2DRD3 | |
| SCHEMBL25366104 | 0.82 | DRD4 (0.54) | DRD4KDM4EALDH1A1DRD2DRD3 | |
| SCHEMBL14587782 | 0.82 | DRD4 (0.53) | POLBDRD4KDM4EACHEDRD2 | |
| SCHEMBL6184188 | 0.81 | LSS (0.65) | KDM4EALDH1A1LSSMAPT | |
| SCHEMBL11552519 | 0.81 | MAPT (0.56) | DRD4KDM4EALDH1A1MAPTCHKA | |
| SCHEMBL1244075 | 0.80 | ALDH1A1 (0.73) | POLBKDM4EALDH1A1MAPT | |
| SCHEMBL7958273 | 0.80 | HRH1 (0.58) | POLBDRD4KDM4ELSS | |
| SCHEMBL16944454 | 0.80 | SIGMAR1 (0.60) | POLBDRD4KDM4EALDH1A1LSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8541572-B2 | Compounds for the treatment of inflammatory disorders | MERCK SHARP & DOHME CORP. (US) | 2013-09-24 | — | — | US | disclosed |
| US-8541572-B2 | Compounds for the treatment of inflammatory disorders | MERCK SHARP & DOHME CORP. (US) | 2013-09-24 | — | — | US | disclosed |
| US-20120010181-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | MERCK SHARP & DOHME CORP. | 2012-01-12 | — | — | US | disclosed |
| US-20120010181-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | MERCK SHARP & DOHME CORP. | 2012-01-12 | — | — | US | disclosed |
| US-6313127-B1 | FOR THERAPY OF HYPERCHOLESTEROLEMIA OR ATHEROSCLEROSIS | ZENECA LIMITED (GB) | 2001-11-06 | — | — | US | disclosed |
| EP-0880501-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PHARMACEUTICAL AGENTS | ZENECA LIMITED (GB) | 1998-12-02 | — | — | EP | disclosed |
| WO-1997028128-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PHARMACEUTICAL AGENTS | ZENECA LIMITED (GB) | 1997-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010181-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | TNF, ADAMTS1, ADAMTS7 | POLB 2043/4885DRD4 4723/4885KDM4E 4576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.